Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07485569 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial

Study acronym: REPOTHYROID-II
StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Jun 1, 2027 → Sep 1, 2027
See other at-risk trials from Radboud University Medical Center

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Not Yet Recruiting → Active, Not Recruiting
    • Primary completion pushed from Jun 1, 2027 to Sep 1, 2027
    • Study completion pushed from Sep 1, 2027 to Dec 1, 2027
    • Publications: details revised at 1 of 1 entry
    v6
  2. Trial status: Not Yet Recruiting to Active, Not Recruitingv5 Show 4 more changesShow less
    • Study sites: 0 to 1
    • Primary completion date: Jun 1, 2027 to Sep 1, 2027
    • Study completion date: Sep 1, 2027 to Dec 1, 2027
    • Start date changed from estimate of Jun 1, 2026 to Aug 1, 2026
  3. Study description revisedv4
  4. Re-verified, no change to tracked fieldsv3
  5. Study description expanded, about 293 wordsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase Ib trial that studies personalized network pharmacology-based drug repurposing in patients with advanced thyroid cancer who have no other treatment options. The main objective is to study if it is feasible to give patients individualized drug combinations selected based on their tumor genetic profile. The secondary objective is to find out whether these treatments are safe and can help control the growth of the patient tumors or stop them from getting worse.
Trial Details
NCT Number NCT07485569
Lead Sponsor Radboud University Medical Center
Collaborators: Maastricht University, EU Horizon, Horizon Europe
Conditions
(from sponsor)		 Thyroid Cancer Stage IV, Anaplastic Thyroid Cancer, Differentiated Thyroid Cancer, Poorly Differentiated Thyroid Carcinoma
Related terms Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov